科倫博泰生物-B(06990.HK)擬折價7.58%配股淨籌19.43億港元 加速產品研發商業化
格隆匯6月5日丨科倫博泰生物-B(06990.HK)發佈公吿,2025年6月5日(交易時段前),公司與配售代理(即Goldman Sachs與Citigroup)訂立配售協議,據此,配售代理已有條件同意按個別(但非共同或共同及個別)基準作為公司代理促使向不少於六名承配人配售(倘未能配售則自行購買)591.8萬股配售股份,配售價為每股配售股份331.8港元。
配售價每股配售股份331.8港元較於最後交易日於聯交所所報收市價每股H股359.00港元折讓約7.58%。假設本公司的已發行股本於本公吿日期至配售事項完成期間並無變動,配售股份(即591.8萬股新H股)佔於本公吿日期現有已發行股本約2.60%;及佔經發行配售股份擴大後已發行股本約2.54%。根據配售協議將予配售的配售股份將根據一般授權配發及發行。公司將向聯交所上市委員會申請批准配售股份上市及買賣。
配售事項的估計所得款項淨額預期約為19.43億港元。公司擬將配售事項的估計所得款項淨額用作以下用途:(i)約80%用於產品的研發、臨牀試驗、註冊備案、製造及商業化;(ii)約15%用於提升內部研發技術能力、加強外部合作及拓展產品管線組合;及(iii)約5%用於補充營運資金及作一般企業用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.